Your browser doesn't support javascript.
loading
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.
M Naeini, Marjan; Newell, Felicity; Aoude, Lauren G; Bonazzi, Vanessa F; Patel, Kalpana; Lampe, Guy; Koufariotis, Lambros T; Lakis, Vanessa; Addala, Venkateswar; Kondrashova, Olga; Johnston, Rebecca L; Sharma, Sowmya; Brosda, Sandra; Holmes, Oliver; Leonard, Conrad; Wood, Scott; Xu, Qinying; Thomas, Janine; Walpole, Euan; Tao Mai, G; Ackland, Stephen P; Martin, Jarad; Burge, Matthew; Finch, Robert; Karapetis, Christos S; Shannon, Jenny; Nott, Louise; Bohmer, Robert; Wilson, Kate; Barnes, Elizabeth; Zalcberg, John R; Mark Smithers, B; Simes, John; Price, Timothy; Gebski, Val; Nones, Katia; Watson, David I; Pearson, John V; Barbour, Andrew P; Waddell, Nicola.
Afiliación
  • M Naeini M; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Newell F; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Aoude LG; Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
  • Bonazzi VF; Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
  • Patel K; Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
  • Lampe G; Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
  • Koufariotis LT; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Lakis V; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Addala V; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Kondrashova O; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Johnston RL; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Sharma S; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Brosda S; Faculty of Medicine, University of Queensland, Brisbane, QLD, 4006, Australia.
  • Holmes O; Anatomical Pathology, Australian Clinical Labs, 2153, Sydney, Australia.
  • Leonard C; Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
  • Wood S; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Xu Q; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Thomas J; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Walpole E; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Tao Mai G; Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
  • Ackland SP; Mater Research Institute, Mater Misericordiae, South Brisbane, QLD, 4101, Australia.
  • Martin J; Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
  • Burge M; Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
  • Finch R; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, 2298, Australia.
  • Karapetis CS; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, 2298, Australia.
  • Shannon J; Royal Brisbane and Women's Hospital, Herston, QLD, 4029, Australia.
  • Nott L; Royal Brisbane and Women's Hospital, Herston, QLD, 4029, Australia.
  • Bohmer R; Flinders University Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA, 5042, Australia.
  • Wilson K; Nepean Cancer Care Centre, Nepean Hospital, Sydney, NSW, 2747, Australia.
  • Barnes E; Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.
  • Zalcberg JR; Department of General Surgery, Royal Hobart Hospital, Hobart, TAS, Australia.
  • Mark Smithers B; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.
  • Simes J; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.
  • Price T; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Gebski V; Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
  • Nones K; Faculty of Medicine, University of Queensland, Brisbane, QLD, 4006, Australia.
  • Watson DI; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.
  • Pearson JV; Medical Oncology Unit, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, 5011, Australia.
  • Barbour AP; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.
  • Waddell N; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Nat Commun ; 14(1): 3155, 2023 05 31.
Article en En | MEDLINE | ID: mdl-37258531
ABSTRACT
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures. We also show that positron emission tomography non-responders have more sub-clonal genomic copy number alterations. Transcriptomic analysis categorises patients into four immune clusters correlated with survival. The immune suppressed cluster is associated with worse survival, enriched with myeloid-derived cells, and an epithelial-mesenchymal transition signature. The immune hot cluster is associated with better survival, enriched with lymphocytes, myeloid-derived cells, and an immune signature including CCL5, CD8A, and NKG7. The immune clusters highlight patients who may respond to immunotherapy and thus may guide future clinical trials.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudio: Guideline Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudio: Guideline Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Australia